India's largest drug maker Ranbaxy Laboratories has managed to capture less than 3% market share in the generic Lipitor segment during initial days of its launch in the US.
According to a J P Morgan report, Watson and Ranbaxy, the two generic drug makers collectively captured 14.6% of US prescription volume of the cholesterol-lowering drug, media reports said. J P Morgan report had cited data from prescription-drug tracker IMS Health.
About 97.6% of the generic versions were from Watson in the first few days, with Ranbaxy holding the remainder, it added.
On November 30, the Indian drug maker had launched its low-cost version of the drug after getting regulatory approvals hours before the scheduled launch date. Lipitor, the original drug is the world's best selling drug with annual sales of $7.89 billion in the US alone.
Analysts in India expect Ranbaxy to earn as much as $600 million during the six month period, where no other drug makers other than the three are allowed to market the drug.
The Gurgaon-based company's share price closed almost unchanged at Rs 406.20.
Pfizer is aggressively trying to protect its market share through unprecedented marketing strategies, including discounts to consumers and health plans during the crucial six months.
Generics drugs are expected to capture about 60% share during the Lipitor exclusivity period, as Pfizer has sought to maintain brand share in the face of generic launches, the note said.
Once the 180 days exclusivity ends, several drug companies such as Teva, Mylan and Dr Reddy's can also start selling their drugs.
According to the J P Morgan report, more than 9.38 lakh prescriptions for drugs containing Lipitor's active ingredient, atorvastatin, were prescribed for the week ended December 2. About 8 lakh or 85.4% were written for the branded Lipitor.
According to a J P Morgan report, Watson and Ranbaxy, the two generic drug makers collectively captured 14.6% of US prescription volume of the cholesterol-lowering drug, media reports said. J P Morgan report had cited data from prescription-drug tracker IMS Health.
About 97.6% of the generic versions were from Watson in the first few days, with Ranbaxy holding the remainder, it added.
On November 30, the Indian drug maker had launched its low-cost version of the drug after getting regulatory approvals hours before the scheduled launch date. Lipitor, the original drug is the world's best selling drug with annual sales of $7.89 billion in the US alone.
Analysts in India expect Ranbaxy to earn as much as $600 million during the six month period, where no other drug makers other than the three are allowed to market the drug.
The Gurgaon-based company's share price closed almost unchanged at Rs 406.20.
Pfizer is aggressively trying to protect its market share through unprecedented marketing strategies, including discounts to consumers and health plans during the crucial six months.
Generics drugs are expected to capture about 60% share during the Lipitor exclusivity period, as Pfizer has sought to maintain brand share in the face of generic launches, the note said.
Once the 180 days exclusivity ends, several drug companies such as Teva, Mylan and Dr Reddy's can also start selling their drugs.
According to the J P Morgan report, more than 9.38 lakh prescriptions for drugs containing Lipitor's active ingredient, atorvastatin, were prescribed for the week ended December 2. About 8 lakh or 85.4% were written for the branded Lipitor.
No comments:
Post a Comment